Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG.

Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8.

2.

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD.

Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1515940. [Epub ahead of print]

PMID:
30277102
3.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G.

Leukemia. 2015 Jul;29(7):1578-86. doi: 10.1038/leu.2015.48. Epub 2015 Feb 24.

PMID:
25708834
5.

Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.

Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S.

Cancer Biomark. 2009;5(3):117-25. doi: 10.3233/CBM-2009-0597.

PMID:
19407366
6.

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C.

Mol Cancer Ther. 2008 Mar;7(3):455-63. doi: 10.1158/1535-7163.MCT-07-2136.

7.

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

8.
9.

The COP9/signalosome complex is conserved in fission yeast and has a role in S phase.

Mundt KE, Porte J, Murray JM, Brikos C, Christensen PU, Caspari T, Hagan IM, Millar JB, Simanis V, Hofmann K, Carr AM.

Curr Biol. 1999 Dec 2;9(23):1427-30.

10.

Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes.

Flaggs G, Plug AW, Dunks KM, Mundt KE, Ford JC, Quiggle MR, Taylor EM, Westphal CH, Ashley T, Hoekstra MF, Carr AM.

Curr Biol. 1997 Dec 1;7(12):977-86.

11.

On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.

Mundt KE, Golsteyn RM, Lane HA, Nigg EA.

Biochem Biophys Res Commun. 1997 Oct 20;239(2):377-85.

PMID:
9344838
12.

The family of polo-like kinases.

Golsteyn RM, Lane HA, Mundt KE, Arnaud L, Nigg EA.

Prog Cell Cycle Res. 1996;2:107-14. Review.

PMID:
9552388

Supplemental Content

Loading ...
Support Center